DNY59 We previously covered Novo Nordisk (NVO) (OTCPK:NONOF) stock in April 2024, discussing why we had maintained our Buy rating then, attributed to the multiple expansions in its manufacturing/fill finish capacities, with the ongoing shortages still implying immense consumer demand. We believed that these capex would eventually be accretive to its top/bottom lines, especially since the Pfizer's (PFE) CEO, Albert Bourla, had estimated an obesity market size of up $150B. Since then, NVO has charted new  ...